Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 29 of the 29 references it cites were found in a registry or an index.

Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*

Alhazzani, Waleed, Lim, Wendy, Jaeschke, Roman Z., Murad, Mohammad Hassan, Cade, Jack, Cook, Deborah J. · 2013 · Critical Care Medicine

Abstract

OBJECTIVE: Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this systematic review was to systematically review the efficacy and safety of heparin thromboprophylaxis in medical-surgical patients in the ICU. DATA SOURCES: We searched EMBASE, MEDLINE, the Cochrane Controlled Trials Register, Clinicaltrials.gov, and personal files through May 2012. STUDY SELECTION: Randomized trials in adult medical-surgical ICU patients comparing any heparin (unfractionated heparin or low-molecular-weight heparin) with each other or no anticoagulant prophylaxis, evaluating deep vein thrombosis, pulmonary embolism, major bleeding, or mortality. DATA EXTRACTION: Independently, in duplicate, we abstracted trial characteristics, outcomes, and risk of bias. DATA SYNTHESIS: Seven trials involved 7,226 patients. Any heparin thromboprophylaxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41, 0.63]; p<0.0001; I=77%) and pulmonary embolism (risk ratio, 0.52 [95% CI, 0.28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25]; p=0.43). Major bleeding (risk ratio, 0.82 [95% CI, 0.56, 1.21]; p=0.32; I=50%) and mortality (risk ratio, 0.89 [95% CI, 0.78, 1.02]; p=0.09; I=0%) rates were similar. Compared with unfractionated heparin, low-molecular-weight heparin reduced rates of pulmonary embolism (risk ratio, 0.62 [95% CI, 0.39, 1.00]; p=0.05; I=53%) and symptomatic pulmonary embolism (risk ratio, 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25]; p=0.44; I=0%), major bleeding (risk ratio, 0.97 [95% CI, 0.75, 1.26]; p=0.83; I=0%), or mortality (risk ratio, 0.93 [95% CI, 0.82, 1.04]; p=0.20; I=31%). CONCLUSIONS: Trial evidence to date suggests that any type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgical critically ill patients, and low-molecular-weight heparin compared with bid unfractionated heparin decreases pulmonary embolism and symptomatic pulmonary embolism. Major bleeding and mortality rates do not appear to be significantly influenced by heparin thromboprophylaxis in the ICU setting. Trial methodology, indirectness, and the heterogeneity and imprecision of some results temper inferences from this literature.

Overview

Integrity signals

Registry

Crossref · 10.1097/ccm.0b013e31828cf104

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. Moser, 1981, JAMA, 246, 1422, 10.1001/jama.1981.03320130028018 · doi:10.1001/jama.1981.03320130028018
  2. Goldhaber, 2000, J Am Coll Cardiol, 35, 325A

Cited by

See all 170

Metadata

Authors
Alhazzani, W., Lim, W., Jaeschke, R. Z., Murad, M. H., Cade, J., & Cook, D. J.
Affiliations
  • McMaster University (CA)
  • Mayo Clinic (US)
  • The Royal Melbourne Hospital (AU)
Venue
Critical Care Medicine
Published
2013-09
Volume
41
Issue
9
Pages
2088-2098
ISSN
0090-3493 (ISSN-L)
OpenAlex
W2321905524
Cited by
168
References
29
Citations by year
2026: 9 · 2025: 3 · 2024: 10 · 2023: 11 · 2022: 19 · 2021: 15 · 2020: 23 · 2019: 19 · 2018: 8 · 2017: 9 · 2016: 10 · 2015: 13 · 2014: 16 · 2013: 3
FWCI
12.18
Type
journal article
Language
en
Open access
closed
Locations
  • Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
Keywords
thromboprophylaxis, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, major bleeding, mortality, intensive care unit patients, symptomatic pulmonary embolism, quality metrics, risk of bias
MeSH terms
Anticoagulants, Heparin, Low-Molecular-Weight, Hospitalization, Humans, Intensive Care Units, Randomized Controlled Trials as Topic, Critical Illness, Treatment Outcome, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*. https://app.cochat.ai/papers/10.1097/ccm.0b013e31828cf104
The paper
Alhazzani, W., Lim, W., Jaeschke, R. Z., Murad, M. H., Cade, J., & Cook, D. J. (2013). Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e31828cf104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.